P/E at 36.01 vs Industry's 35.12: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Confidence Amid Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.01, slightly above the Pharmaceuticals & Biotechnology industry average of 35.12. This 2.5% premium suggests investors are willing to pay a marginally higher price for earnings, reflecting expectations of relative stability or growth within a sector that has seen mixed results. The premium is not excessive but indicates a degree of confidence in the company’s earnings quality and future prospects. Sun Pharma’s market capitalisation of ₹4,51,794.77 crores places it firmly in the large-cap category, further supporting its valuation standing.

Performance Across Timeframes: Consistent Outperformance with Recent Stability

Examining returns over various periods reveals Sun Pharmaceutical Industries Ltd has delivered solid gains relative to the Sensex. Over one year, the stock has risen 12.17%, contrasting with the Sensex’s decline of 6.39%. The three-month performance is also robust at 11.11%, outperforming the Sensex’s 6.27% gain. Year-to-date, the stock is up 9.49% while the Sensex remains down 8.57%. This consistent alpha generation across short and medium terms highlights resilience in a sector that has seen 12 positive, 3 flat, and 5 negative results recently.

Shorter-term momentum is positive as well, with a 1-month gain of 5.23% versus the Sensex’s 4.81%, and a 1-week rise of 1.12% compared to 1.06% for the benchmark. The stock’s 1-day performance of 0.61% slightly outpaced the Sensex’s 0.54%, although it underperformed its sector by 0.49% on the same day. This suggests that while Sun Pharma remains a strong performer, intra-day sector dynamics can create short-term divergences — is this a temporary fluctuation or a sign of shifting sector leadership? The stock’s proximity to its 52-week high, just 2.52% away, further underscores its recent strength.

Moving Average Configuration: Bullish Across All Key Averages

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across both short and long-term horizons. This comprehensive bullish configuration suggests sustained buying interest and momentum, which is not always common in the Pharmaceuticals & Biotechnology sector, where volatility can be pronounced.

However, the stock has recently fallen after two consecutive days of gains, opening at ₹1870 and trading flat at that level during the day. This pause after a short rally raises the question of whether the current momentum can be maintained or if a consolidation phase is imminent — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The fact that the stock remains close to its 52-week high supports the view that the overall trend remains intact despite short-term fluctuations.

Sector Context: Mixed Results Amidst Steady Large-Cap Performance

The Pharmaceuticals & Biotechnology sector has delivered a mixed bag of results recently, with 12 companies reporting positive outcomes, 3 flat, and 5 negative. Within this environment, Sun Pharmaceutical Industries Ltd stands out for its consistent outperformance and stable valuation premium. The sector’s average P/E of 35.12 reflects moderate investor optimism, which aligns closely with Sun Pharma’s own valuation metrics.

This relative stability contrasts with some sector peers that have experienced sharper valuation swings or performance volatility, highlighting Sun Pharma’s role as a large-cap anchor within the industry. How will this sector positioning influence the stock’s near-term trajectory?

Rating Context: Previously Rated Hold, Now Reassessed

On 8 June 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold status by MarketsMOJO. The Mojo Score of 74.0 reflects a solid overall assessment, though the current rating is not disclosed. This reassessment comes amid the company’s steady performance and valuation premium, suggesting a re-evaluation of its risk-reward profile in light of recent data.

Investors may find it pertinent to consider how this updated rating aligns with the stock’s technical strength and consistent outperformance — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Long-Term Returns: Strong Growth with Some Relative Moderation

Over a three-year horizon, Sun Pharmaceutical Industries Ltd has delivered an impressive 82.43% return, significantly outpacing the Sensex’s 19.50% gain. The five-year performance is even more striking, with a 176.59% increase compared to the Sensex’s 48.46%. However, the ten-year return of 146.47% trails the Sensex’s 187.05%, indicating some relative moderation over the longest timeframe.

This pattern suggests that while Sun Pharma has been a strong growth story in recent years, its earlier decade-long performance was less dominant. The recent acceleration aligns with the company’s current valuation premium and technical strength, reinforcing the narrative of a large-cap stock that has gained favour in the last half-decade.

Conclusion: Data Reflects a Balanced Yet Positive Outlook

The comprehensive data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation premium with consistent outperformance across multiple timeframes. Its technical positioning above all major moving averages signals sustained momentum, while the sector’s mixed results highlight the company’s relative stability.

Previously rated Hold, the recent reassessment and a Mojo Score of 74.0 underscore a positive shift in the stock’s profile. Yet, short-term fluctuations and sector dynamics warrant attention — what is the current rating for Sun Pharmaceutical Industries Ltd, and how should investors interpret this evolving data?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today